gm2-klh vaccine
Biologicalexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 1998 (NCT00003357)
Timeline
Indications
Studied for
Mechanism of action
- Protein-glutamine gamma-glutamyltransferaseImmunity, active
TGM2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gm2-klh vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00005052 | Phase 3 | Dec 1, 1999 | Erasmus University Rotterdam, European Organisation for Research and Treatment of Cancer |
| NCT00003357 | Phase 1 | Jan 1, 1998 | Cornell University, National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 1998 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 1999 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 1999 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1998 |
4 organizations
Page 1 / 1